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Interference with Heme Binding
to Histidine-Rich Protein-2
as an Antimalarial Strategy
of infected erythrocytes to the vascular endothelium of
postcapillary venules, especially in the brain, can lead
to severe clinical complications [2].
During the intraerythrocytic stage, the host hemoglo-
bin is a primary food source of the parasite. Hemoglobin
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Many of the antimalarial drugs act exclusively on the
blood stage of the infection. Quinacrine [6-chloro-9-(4-Summary
diethylamino-1-methylbutylamino)-2-methoxyacridine]
and quinoline-containing drugs, such as chloroquine,The erythrocytic growth stage of Plasmodium falci-
quinine, and mefloquine, are all toxic to the blood stageparum involves hemoglobin proteolysis as the primary
parasite. The mechanism of action of these drugs is notnutrient source with the concomitant release of free
well understood, although they have been hypothesizedheme. The liberated heme is processed by the parasite
to interfere with hemoglobin digestion and heme detoxi-into hemozoin, a polymeric porphyrin dimer. Histidine-
fication within the parasite [5–7].rich protein binds heme and mediates the formation
The heme detoxification pathway of P. falciparum isof hemozoin, which is inhibited by the antimalarial drug
a particularly attractive drug target: (1) it targets thechloroquine. Interference with heme binding was de-
parasites at the stage when they are causing the clinicaltermined using a microtiterplate assay. Combinatorial
pathologies; (2) humans detoxify free heme via the hemelibraries were screened and tested against parasite
oxygenase/biliverdin reductase pathway; hence, a druggrowth, revealing a good correlation between heme
that interferes with heme processing in P. falciparumbinding interference and the inhibition of parasite
will not inhibit heme detoxification in humans; and (3)growth. Several of these compounds retain their po-
inhibition of heme detoxification would lead to a build-tency against a chloroquine-resistant strain of Plas-
up of high concentrations of toxic free heme inside themodium falciparum. The most potent compounds
parasite.have IC50 values less than or equal to 50 nM against
One protein that has been implicated in heme detoxifi-chloroquine-resistant and chloroquine-sensitive para-
cation within P. falciparum is histidine-rich protein 2sites.
(HRP-2), a 30 kDa protein consisting of 35% histidine
residues [8, 9]. HRP-2 has been shown to bind multiple
Introduction molecules of heme and to mediate heme polymerization
in vitro [10, 11]. We have previously demonstrated that
Malaria is one of the most deadly infectious diseases HRP-2 can bind heme via bis-histidyl coordination [11].
in the world, responsible for close to two million deaths Compounds that either inhibit heme binding to HRP-2
per year. Aminoquinoline-based compounds have been or inhibit polymerization of heme bound to HRP-2 should
effective in the treatment of the disease; however, drug- be toxic to the parasite. Inhibition of heme binding could
resistant parasites have emerged to the most commonly occur in two ways. Inhibition could occur via the seques-
used aminoquinoline, chloroquine. More ominous is the tration of heme in solution by the formation of semistable
appearance of multidrug-resistant organisms, making solution complexes. Complexes of this type have been
development of novel antimalarial drugs imperative [1]. reported with the antimalarial chloroquine [12–14], and
The life cycle of the malaria parasite is complex and we have evidence that chloroquine inhibits heme bind-
includes both an Anopheles mosquito and a human host. ing to HRP-2 by this mechanism (our unpublished re-
For a portion of the life cycle, the malaria parasite devel- sults). Alternatively, inhibition could come about by
ops within human red blood cells, and it is during this compounds binding to the HRP-2 heme complex or to
intraerythrocytic stage that many of the clinical symp- HRP-2 alone, thereby preventing heme from binding
toms associated with malaria, including recurring fever, (Figure 6). Here, we present our data describing (1) iden-
chills, and anemia are observed. The most deadly of all tification of compounds that inhibit heme binding to
malaria parasites is Plasmodium falciparum. Adherence HRP-2 and (2) the effects of these heme binding inhibi-
tors on parasite growth.
In order to screen a large number of compounds, we5 Correspondence: marletta@cchem.berkeley.edu
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have developed a novel microplate-based assay that
provides a method for a quick and efficient screen. Using
this assay, we found several compounds that strongly
inhibit heme binding to HRP-2. These compounds were
also screened in bioassays to determine their ability to
inhibit parasite growth. The results of these two methods
revealed a strong correlation between inhibition of heme
binding and inhibition of parasite growth.
Results
Heme Binding Assay
HRP-2-bound heme has a Soret peak at 414 nm, while
free heme (i.e., unbound to HRP-2) has a broad, low-
extinction Soret peak centered around 386 nm. In the
heme binding assays described here, heme binding to
HRP-2 was followed by monitoring the increase in the
Soret absorbance caused by heme binding. Absorbance
contributions from the test compounds and free heme
have been subtracted. Inhibition of, or interference with,
heme binding led to a decrease in the Soret at 414 nm.
Screening of Acridine Derivatives
We obtained several chloroquine and quinacrine ana-
logs from the library of compounds at Parke-Davis Phar-
maceutical Co. (now Pfizer Global Research & Develop-
ment). Compounds 1, 2, 3, and 4 appeared to be the
most potent inhibitors of heme binding. These acridine
derivatives are shown in Figure 1A. The potency of com-
pounds 1–4 to inhibit heme binding to HRP-2 was com-
pared with quinacrine, an acridine-based antimalarial
drug. Results of the heme titration experiments using
quinacrine, 1, and 2 are shown in Figures 1B, 1C, and
1D, respectively. Heme titration results for 3 and 4 are
very similar to Figures 1C and 1D (data not shown).
Compounds 1–4 are about 3-fold more potent than quin-
acrine. As shown in Figure 1, the addition of more heme
overcomes the inhibition. The heme titration results in
Figure 1 are not simple linear decreases in absorbance,
suggesting that the inhibition of heme binding is compli-
cated and could likely involve, in part, a heme-com-
pound complex in solution.
The effects of compounds 1 and 2 on parasite growth
were examined. The two compounds were tested
against both the chloroquine-sensitive (HB-3) and the
chloroquine-resistant (Dd-2) strains. Compound 1 inhib-
ited the growth of P. falciparum cultured in erythrocytes,
with IC50 value of 40 nM against both the chloroquine-
sensitive and the chloroquine-resistant strains. The IC50
values for compound 2 were determined to be 50–100
nM and 100 nM against the chloroquine-sensitive and
-resistant strains, respectively.
Figure 1. The Effect of Quinacrine and Analogs on Heme Binding
Library Development and ScreeningThe chemical structures of quinacrine and the analogs used are
A combinatorial library based on general structure 5shown in (A). Effects of (B) quinacrine (Qc), (C) Compound 1, and
(D) 2 on HRP-2-heme binding using the heme titration experiment (Figure 2) was produced with the initial goal of targeting
as described under Experimental Procedures. Heme was simultane- plasmepsin II, a parasite aspartyl protease that cleaves
ously titrated into both the experimental cuvette (containing 0.2 M hemoglobin in the P. falciparum food vacuole. A minor
HRP-2 and varying concentrations of the test compound) and a
byproduct, 6, was identified as a very weak inhibitor ofreference cuvette (containing the test compound), and difference
the plasmepsin II (IC50  20 M) yet was quite potentabsorption spectra were recorded. The y axis is the max of the
against the parasite in cell culture (IC50  100 nM). Asdifference spectra (located at 415 nm). The concentrations of each
compound in M are given in the insets. expected, removal of the stereospecific functional
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Figure 2. General Structure of the Combinatorial Library and the Library-Derived Compounds
Structure 5 was the initial template for library design. Structure 6, a by-product of the synthesis, was determined to be active in parasite
killing but a weak plasmepsin inhibitor. Removal of the stereospecific centers yields structure 7. The general synthetic routes for the combinato-
rial library-derived compounds are described in the Experimental Procedures section. The classes of compounds shown under each section
were developed from the lead compound 7.
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groups from the compound (7 in Figure 2) resulted in a
molecule that was a very poor inhibitor of plasmepsin
II (IC50 250 M). Interestingly, this and others in this
class retained the ability to inhibit parasite growth, indi-
cating that the targeted proteases were not responsible
for the inhibition of parasite growth. Based on this obser-
vation, more compounds were generated using combi-
natorial chemistry methods.
Using the microplate heme binding assay, we
screened the compounds shown in Figure 2 and com-
pared these results with those obtained from the para-
site growth-inhibition assays. Figures 3A and 3B are
representative heme binding assay results. In each case,
heme binding is plotted against the concentration of
heme alone and in the presence of a test compound. In
the absence of test compound, the heme binding curve
shows an increase in ASoret as the concentration of
heme increases, followed by a plateau as the heme
binding sites become saturated. A concentration-
dependent decrease in ASoret is indicative of concentra-
tion-dependent inhibition.
An example of a potent heme binding inhibitor (com-
pound 24) is shown in Figure 3A. The ASoret is minimal
at the three concentrations tested and is essentially zero
at 100 M, indicating that heme binding to HRP-2 has
been almost completely inhibited. Compound 10 is an
example of a weak inhibitor. As seen in Figure 3B, com-
pound 10 has little influence on the binding curve, indi-
cating that 10 is unable to interfere with heme binding
to HRP-2.
The potency of each compound to inhibit heme bind-
ing to HRP-2 was determined by calculating percent
inhibition that resulted at a 1:1 ratio of compound to
heme as follows:
% inhibition  (ANo Compound  AWith Compound)/
(ANo Compound)  100
All of the results of the microtiterplate heme binding
assay and the IC50 values obtained from parasite growth
inhibition studies are compiled in Table 1. A plot of
percent inhibition versus IC50 was constructed (Figure Figure 3. Heme Binding Inhibition Assay and the Relationship to
3C) in order to determine if there is a correlation between Parasite Growth
the ability of each compound to inhibit parasite growth in Effects of (A) a strong inhibitor, compound 24, and (B) a weak inhibi-
culture and the ability to inhibit heme binding to HRP-2. tor, 10, on heme binding by HRP-2 using the microtiterplate assay
described under Experimental Procedures. Compound concentra-For most of the compounds tested, their ability to
tions are given in the insets. The relationship of heme binding toinhibit heme binding is a good predictor of the antipara-
parasite growth is shown in (C). The y axis refers to the results ofsitic potency. Those compounds that are strong inhibi-
the microplate heme binding assay expressed as percent inhibition
tors of heme binding, such as 16, 22, and 24–27, are at 1:1 ratio of the concentrations of the test compound to heme
potent inhibitors of parasite growth, having IC50 values (typically between 30–40 M). The x axis refers to the results of the
in low nanomolar range. Alternatively, 9, 10, 15, 32, and parasite growth-inhibition assay. Points shown in closed circles
were fitted to the equation y  99.653  27.025 log(x), r2  0.844.33 are weak inhibitors of both heme binding and parasite
growth. There were no examples of compounds that
were more potent against the CQ-resistant strain that
were also potent in the heme binding assay. In the CQ- poses the parasite to the toxic properties of free heme
resistant strain, compounds were either equally potent in solution. Several of the compounds derived from the
or less potent in parasite killing. combinatorial library work by forming a solution com-
plex with heme. Shown in Figure 4A are the results with
compound 24. The increase in absorbance at 429 nmMechanism of Inhibition
Figure 6 depicts the several possible ways that com- is similar to the solution complex seen between CQ and
heme. This suggests that some of the active compoundspounds might interfere with heme binding to HRP-2. As
mentioned, CQ is thought to act by forming a relatively may work via a similar mechanism. Some of the less
potent compounds do not induce the same spectralstable solution complex with heme and in doing so ex-
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Table 1. Results of Parasite Growth-Inhibition Assays and
Microtiterplate Heme Binding Inhibition Assays
IC50 (nM)a IC50 (nM)a
CQ-Sensitive CQ-Resistant Heme Bindingb
Compound Strain Strain Inhibition %
8 350 6
9 5000 0
10 5000 0
11 300 47
12 500 26
13 75 25
14 200 – 40
15 5000 – 0
16 15 200 73
17 30 350 37
18 50 50
19 75 24
20 2000 29
21 100 – 62
22 18 130 72
23 125 – 58
24 11 70 84
25 20 80 72
26 25 45 76
27 25 75 91
28 100 200 42
29 130 200 54
30 300 300 26
31 300 300 38
32 1000 10
33 5000 0
34 35 56
35 35 56
Figure 4. Probing the Mechanism of Action of Compound 2436 35 150 48
(A) Formation of a complex between 24 and heme. Compound 24
a The concentration of the test compound that inhibited parasite was titrated into a heme solution as described under Experimental
growth by 50% by the method described in Experimental Proce- Procedures. Addition of compound resulted in a peak at 421 nm,
dures. similar to that seen between chloroquine and heme. Higher concen-
b The inhibition of heme binding as determined by the microtiterplate trations of compound shift the peak maximum to 429 nm.
assay described in Experimental Procedures. The values listed are (B) Microtiterplate heme binding inhibition assay with compound
the percent inhibition observed at an equimolar ratio of compound 24. Heme concentrations of up to 55 M were used with no com-
to heme. pound (open circles), 10 M compound (filled triangles), 25 M
compound (open squares), and 50 M compound (filled circles).
With increased addition of heme, inhibition by the compound is
overcome, and the A415 increases to levels similar to those reached
shift. We further explored potential mechanisms of inhi- in the absence of compound.
bition outlined in Figure 6 by testing if heme could re-
verse the inhibitory effect. The results of the heme rever-
sal experiment with 24 are shown in Figure 4B. It is clear Discussion
from this experiment that heme reverses the inhibition.
If the inhibitory effect was due to the formation of a Microplate Heme Binding Inhibition Assay
stable solution complex between heme and 24 (complex With the rise of drug resistance to the commonly used
[B] in Figure 6), then we would expect to see results like antimalarial drugs, there is a critical need for novel anti-
those in Figure 4A. However, we cannot rule out the malarial drug development and consequently a need for
participation of complexes [C] and [D], since we have novel potential targets. The heme detoxification path-
no measure of the relative affinities in question. In fact, way of P. falciparum has been studied in this context.
when an experiment like that in Figure 4A was carried This pathway meets two important criteria for an ideal
out with a weak inhibitor, 10, there was a much weaker drug target: (1) it is unique to the parasite, and (2) it
intensity peak at 429 but a significant decrease in the is required for parasitic survival. HRP-2 appears to be
heme absorption in the sample, suggestive of a heme- intimately involved in heme processing. First, HRP-2 has
compound complex but not as strong and certainly dif- a large capacity for binding free heme [11]. The ability
ferent than that which forms with strong inhibitors (data of HRP-2 to act as a heme sponge may be its most
not shown). The complex that forms with weak inhibitors important function since the parasite is exposed to high
such as 10 also seems to form more slowly (data not heme concentrations via the catabolism of hemoglobin.
shown). The overall conclusion is that there are likely to Second, once it binds heme, HRP-2 appears to play a
be multiple mechanisms of inhibition, and the current role in heme polymerization, thereby detoxifying free
assays do not help to distinguish among the possibil- heme [10]. It follows, then, that compounds that interfere
with HRP-2 heme binding would lead to an increase inities.
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pensive, and slow, prohibiting screening of a large num-
ber of compounds. Moreover, the results of growth inhi-
bition studies do not provide any information about
either the target or the mode of action of a drug. The
microplate-based assay reported here allows for an
easy, efficient, and quick method of screening a large
number of compounds.
There are many important advantages to monitoring
heme binding rather than heme polymerization. First,
heme binding is a very rapid process: at pH 7.0, heme
binding by HRP-2 is complete within the mixing time.
Heme polymerization, on the other hand, is a much
slower process, requiring several hours. There are sev-
eral conflicting reports about the reaction conditions
and the time required for heme polymerization. Most
report reaction time of 12–18 hr [10, 15, 16]. The fastest
reaction time reported thus far is 30 min at 60C [17].
However, reports from other groups [18] and our own
work cannot duplicate heme polymerization under these
conditions (data not shown). Second, in addition to be-
ing slow, using heme polymerization to screen potential
antimalarial drugs is cumbersome, as several wash
steps are required to separate free heme from polymer-
Figure 5. Synthetic Precursors ized heme once the polymerization reaction has been
Compounds synthesized in the combinatorial synthesis were de- terminated [10, 15, 16]. The heme binding inhibition
rived from these synthetic precursors. assay described here, on the other hand, requires no
handling steps other than adding HRP-2, heme, and the
test compound. No additional wash steps are neces-
free heme concentration and should therefore be toxic sary. Third, experiment-to-experiment variability is mini-
to the parasite. mal using the microplate heme binding assay. Con-
In order to facilitate screening of compounds that can versely, the number of wash steps required to separate
inhibit heme binding to HRP-2, we developed a quick, free heme introduces additional sources of error to the
efficient, and inexpensive method of screening a large heme polymerization assay; hence, experiment-to-
number of compounds. These compounds should also experiment variability can be significant. We did find,
inhibit heme polymerization and therefore act as antima- however, that the most consistent results with the mi-
larials. Bioassays, such as the parasite growth inhibition croplate assay were obtained when the protein was
assay that monitors the effects of small molecules on added last. As mentioned above (and shown in Figure
the growth of cultured parasite, are labor intensive, ex- 6), inhibition is not simple and some complexes that do
form tend to precipitate. Spectral titrations generally
reflect this complexity, and consequently comparisons
of compound families are difficult. There are clear cases
when part of the inhibition mechanism is due to a solu-
tion complex between the test compound and heme
and other cases where the compound leads to either
heme or protein precipitation (data not shown).
9-Aminoquinoline Compounds
Quinacrine is a 9-aminoacridine derivative that had been
widely used to treat malaria until it was replaced by
chloroquine in the 1940s. The mechanism of action of
quinacrine is unknown [5]; however, the fact that quina-
crine, 4-aminoquinolines (e.g., chloroquine), cinchona
alkaloids (e.g., quinine), and quinolinemethanols (e.g.,
mefloquine) all share certain structural features (i.e., a
hydrophobic, planar heterocyclic ring with a functional
group containing a weakly basic nitrogen atom) sug-
Figure 6. Inhibition of Heme Binding to HRP-2 gests that they may share some similarities in their
This scheme depicts the potential mechanisms by which heme bind- mechanism of action. Previous work has suggested that
ing could be inhibited. Formation of complex [A] would lead to a mechanism of action of chloroquine, mefloquine, and
loss in the A415. This could occur by formation of complex [B], and quinine may involve (1) interaction of these compoundssome of the compounds used in this study appear to act in this way.
with free heme [19, 20] and (2) subsequent inhibition ofThe inhibition results do not rule out inhibitory action by reversing
complex [C] or [D]. heme polymerization [5, 21, 22]. However, this hypothe-
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sis remains unproven and the correlation between bind- IC50 values below 100 nM against the chloroquine-resis-
tant strain and IC50 values under 30 nM against the chlo-ing to heme and blockade of polymerization is inconsis-
roquine-sensitive strain.tent [12].
It is interesting that these new compounds are moreThe data presented here clearly demonstrate that
potent against the chloroquine-sensitive strain than thequinacrine can inhibit heme binding to HRP-2, although
resistant strain, even though they are structurally unre-the plate assay does not clarify the mechanism of this
lated to chloroquine. In particular, 16 and 17 have anti-inhibition. This finding supports the proposal that the in
plasmodial potency that is at least 10-fold weaker in thevivo mechanism of action of quinacrine involves interfer-
chloroquine-resistant strain then it is in the chloroquine-ence with heme detoxification. The four 9-aminoacri-
sensitive strain. Possibly, there may be some crossresis-dines that we found to be even more potent (by about
tance such that the mechanism that confers chloroquine3-fold) than quinacrine in their ability to inhibit heme
resistance may affect these compounds as well.binding suggests that modification of both the position
As mentioned above, the resistance of Plasmodiumand the nature of the substituents on the heterocyclic
falciparum to commonly used drugs such as chlo-ring can lead to increased potency. Compounds 1–4
roquine and related compounds will seriously hamperdiscussed here all have very similar heme binding curve
the ability to treat and control the disease that afflictsprofiles, indicating that a chloro-, methyl-, methoxy-, or
millions every year. Rational drug design has not playedphenoxy- group at the C–6 position makes little differ-
a very important role in treating malaria. The Plasmo-ence in their ability to inhibit heme binding.
dium sequencing project underway will be an importantBoth compounds 1 and 2 were toxic to the chlo-
step in providing novel targets for new pharmaceuticals.roquine-sensitive and chloroquine-resistant strains,
Heme polymerization is clearly important to the organ-with 1 having an IC50 value that is 2-fold less than that of
ism, and here we have demonstrated the utility of the2. The observation that both compounds were similarly
microtiterplate heme binding inhibition assay as a first-effective against the chloroquine-resistant strain as the
line screening tool for target-based drug design, tar-chloroquine-sensitive strain could be important in the
geting the HRP-2-mediated heme detoxification path-effort to treat chloroquine-resistant organisms.
way of P. falciparum. The microtiterplate heme binding
assay makes screening of a large number of compounds
possible. Moreover, the heme binding assay seems toCombinatorial Library Compounds
correlate reasonably well with the inhibition of parasiteThough this new class of compounds is structurally un-
growth. As we have reported here, potent new com-related to aminoquinolines, they possess a basic amine,
pounds to treat the disease have been found and repre-a functionality thought to be important in chloroquine
sent a new direction in treating this disease.accumulation inside the food vacuole. Additionally, they
all possess heterocyclic ring systems. As the food vacu-
Significanceole is the site of hemoglobin catabolism as well as heme
detoxification, we tested the possibility that these com-
Malaria continues to be one of the most common hu-
pounds could be playing a role by interfering with heme
man infections, responsible for 1–2 million deaths per
processing. Using the heme binding inhibition assay year. While effective treatments exist, resistance to
described here, we screened all of the compounds for commonly used drugs such as chloroquine clearly in-
their ability to inhibit heme binding by HRP-2. dicates that novel therapies must be developed. The
The results of the heme binding assay and the parasite histidine-rich proteins, typified by HRP-2, are a unique
growth-inhibition assay demonstrated that antiparasitic class of proteins that act as a heme sponge and medi-
potency correlated well with the ability of these com- ate the formation of hemozoin, the catabolic, dimeric
pounds to inhibit heme binding to HRP-2 (Figure 3C). end product of heme metabolism in the parasite. Inter-
The mode of action of many of the antiplasmodial agents ference in this detoxification pathway is important to
effective against the blood-stage parasite are thought parasite survival, especially during the blood-stage in-
to involve hemoglobin degradation, heme, or heme de- fection, when catabolism of hemoglobin serves as the
toxification. For instance, it has been hypothesized that nutrient source. With the development of a microtiter
quinoline-containing antimalarial drugs, such as chlo- plate assay for inhibition of heme binding to HRP-2,
roquine, quinine, and mefloquine, interfere with heme we have explored the relationship of the inhibition of
detoxification. Though none of the compounds in this heme binding to HRP-2 to parasite killing, primarily
new class structurally resemble quinoline-containing using a portion of a combinatorial library developed
antimalarial drugs, there is a good correlation between against the parasite. Our results show that parasite
the IC50 values and the level of heme binding inhibition. killing is directly correlated to interference with heme
Though not definitive, this finding is certainly suggestive binding to HRP-2 and suggest further that inhibition
of the heme detoxification pathway being involved in of heme binding to HRP-2 may be the mechanism of
the mode of action of these compounds. Likewise, it action of chloroquine. Taken together, our results
point the way toward novel therapies to treat this im-remains to be determined whether the heme binding
portant human disease.inhibitors act by (1) interacting with HRP-2, thereby pro-
hibiting HRP-2 from binding heme; or (2) interacting with
Experimental Proceduresheme, thereby sequestering heme from binding HRP-2
(Figure 6). Materials
Several of these compounds (24–27) retain their po- HRP-2 was expressed and purified as described previously [10, 11].
Compounds 1–4 were a generous gift from Parke-Davis Pharmaceu-tency against the chloroquine-resistant strain. All have
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tical (now Pfizer Global Research & Development). Ninety-six-well, removed using standard Pd(0) catalyzed methods, and the resulting
amine was treated with various aldehydes under reductive condi-flat-bottom microplates were from Costar. All other chemicals were
purchased from Sigma Chemical Co. (St. Louis, MO) unless other- tions (NaBH3CN). Simultaneous removal of the Boc group and purifi-
cation of the products was achieved using a strongly acidic ionwise stated.
Materials for synthesis: ion exchange resin (AG MP-50, cat. no. exchange resin (P-SO3H). Finally, NH3/MeOH was applied to the
amine-bound resin to release the free amine (compounds 16–20,143-0841) was purchased from Bio-Rad. Anhydrous N,N-dimethy-
formamide (DMF) was purchased from Aldrich. Chloroform (CHCl3) 36). Removal of the Boc group from the intermediate from step 4
directly generates 32.was passed through basic alumina prior to use. Flash column chro-
matography was carried out with Merck 60 230-400 mesh silica gel. Synthesis of Compound 23
(1) Compound B (R3  CH2C6H5) was N-debenzylated (using H2,1H- and 13C-NMR spectra were recorded using a UCB Bruker AMX-
400 and AM-400 spectrometers. Pd/C, AcOH, and EtOAc) and coupled to C6H5CH2CO2H, thereby
generating an N-acylated piperidine. (2) Next, the product of step
1 was treated with NaN3 and NaI in DMF to generate the azideChemistry
adduct. (3) Reduction of the azide-containing intermediate from stepThe new class of antimalarials was built around a common basic
2 was followed by reductive amination with 4-benzyloxy-1-benzal-structure A (Figure 5) containing four sites of possible diversity (i.e.,
dehyde. (4) The Boc group was removed to yield compound 23.R1, linker, R2, and R3 ). A brief summary of the synthetic scheme is
Synthesis of Compound 24included here. A more detailed description of the synthesis with com-
(1) Compound B (R3CH2C6H5) was N-debenzylated using H2, Pd/C,plete compound characterization will be reported elsewhere [25].
AcOH, and EtOAc. (2) To the intermediate produced in step 1 was
added Et3N and allyl chloroformate. (3) The product purified fromR1 Site Modification
step 2 was treated with NaN3 and NaI in DMF to generate the azideSynthesis of Compounds 8–10
adduct. (4) Treatment of the azide-containing intermediate from step(1) 4-amino-1-benzylpiperidine was reacted with 1-bromo-3-chloro-
3 with SnCl2, PhSH, and Et3N provided the free amine, which waspropane in CH3CN. (2) The product from step 1 was then treated
coupled with 4-benzyloxy-benzoic acid. (5) The Alloc protectionwith di-t-butyl dicarbonate in THF and purified on a silica gel column
group from the step 4 intermediate was removed using standardto generate B (where R3  CH2C6H5) (refer to Figure 5). (3) B (R3 
Pd(0) catalyzed methods, and the resulting amine was treated withCH2C6H5) was treated with NaN3 and NaI in DMF. (4) SnCl2, PhSH,
(C6H5)2CHCH2CHO under reductive conditions (NaBH3CN). Simulta-Et3N, and the intermediate from step 3 were added together in THF
neous removal of the Boc group and purification of the productsto produce D (refer to Figure 5). (5) D was treated with a variety of
was achieved using a strongly acidic ion exchange resin (P-SO3H).carboxylic acids (i.e., R1CO2H) and applied to solid supported EDC
The amide was then reduced to the corresponding amine using(P-EDC). Removal of the Boc group and purification of the products
LiAlH4 in THF.were simultaneously achieved using a strongly acidic ion exchange
Synthesis of Compound 33resin (P-SO3H). Next, NH3/MeOH was applied to the amine-bound
Compound 33 was obtained in two straightforward steps by Mitsu-resin to release the free amine products 8–10.
nobu reaction (DIAD, Ph3P, THF) of (R ) glycidol with phthalimide
followed by epoxide opening with 1-N-benzyl-4-aminopiperidine.Linker Modification
Synthesis of Compounds 25–31, 34Amide (11)
(1) Treatment of 4-amino-1-benzylpiperidine with di-t-butyl dicarbo-4-benzyloxy-3,5-dimethoxybenzoic acid was coupled to amine E,
nate in THF provides the N-Boc protected material. (2) Treatmentwhich was prepared according to the sequence described for D,
of the intermediate from step 1 with Pd/C and H2 provides theexcept that 1-bromo-4-chlorobutane was used in place of 1-bromo-
secondary amine, which is coupled with a variety of aldehydes3-chloropropane. The acid and E were coupled, and then the prod-
[ClC6H4CH2CHO, (C6H5)2CHCHO, C6H5CHO, C6H11CHO, anduct was deprotected to provide 11 exactly according to the proto-
C6H11CH2CHO] under reductive conditions (NaBH3CN). The interme-cols used to prepare products 8–10.
diate from step 2 is then treated under reductive conditionsEther (12)
(NaBH3CN) with N-substituted 4-piperidones [N-substitution is4-benzyloxy-3,5-dimethoxy-alcohol was treated with NaH followed
CH3CH2-, ClC6H4CH2CH2-, (C6H5)2CHCH2-, C6H5CH2-, C6H11CH2-, andby alkyl chloride B (R3  CH2C6H5). The Boc group was removed as
C6H11CH2CH2-] to provide 25–31, 34.described previously to generate 12.
Amine (35)Reverse Amide (13, 21, and 22)
11 was reduced using LiAlH4 in THF.4-benzyloxyaniline was coupled with N-Boc-	-alanine. After cleav-
age of the Boc group, N-R3-piperidone was added and the mixture
was treated with NaHB(OAc)3 to generate compounds 13, 21, and Heme Titration
22. (R3 is CH2C6H5 for compound 13, CH2C6H11 for compound 21, All electronic absorption spectra were recorded on a Cary 3E (double
and CH2CH(C6H5)2 for compound 22.) beam) spectrophotometer with the temperature set at 37C using a
Reverse Amide (14)
Neslab RTE-100 temperature controller.
4-benzyloxybenzylamine was coupled with N-Boc-	-alanine. After
A stock solution of 1 mM heme was made in 0.1 M NaOH, and
cleavage of the Boc group, N-benzyl-piperidone was added and the
its concentration was determined spectroscopically (
385  58.44mixture was treated with NaHB(OAc)3 to generate compound 14. mM1cm1) [23]. This heme solution was simultaneously titrated into
two cuvettes. One cuvette contained 0.2 M HRP-2 and varying
R2 Site Modification concentrations of the test compound in 100 mM HEPES (pH 7.0).
Synthesis of Compound 15 The second cuvette, the reference cuvette, contained only the test
4-benzyloxy-3,5-dimethoxybenzoic acid was coupled to 7. After Boc compound in equal concentration as the first cuvette. Heme was
deprotection, the R2 site modification was achieved by treating this added in 1 M increments, and difference absorption spectra were
intermediate with acetyl chloride to generate compound 15. recorded after each addition. The difference spectra had a peak
at 416 nm and a trough at 368 nm. The heme binding curve was
R3 Site Modification constructed by plotting A415 versus the heme concentration.
Synthesis of Compounds 16–20, 32, 36
(1) Compound B (R3  CH2C6H5) was N-debenzylated using H2, Pd/
C, AcOH, and EtOAc. (2) To the intermediate produced in step 1 Compound Titration
All electronic absorption spectra were recorded on a Cary 300 spec-was added Et3N and allyl chloroformate. (3) The product purified
from step 2 was treated with NaN3 and NaI in DMF to generate the trophotometer at 37C. The sample and reference cuvettes con-
tained 10 M heme in 100 mM HEPES (pH 7.0). A stock solution ofazide adduct. (4) Treatment of the azide-containing intermediate
from step 3 with SnCl2, PhSH, and Et3N provided the free amine, 2 mM test compound was prepared in 100 mM HEPES. The test
compound was added in 2 M increments to the sample cuvette.which was coupled with 4-benzyloxy-3,5-dimethoxybenzoic acid.
(5) The Alloc protection group from the step 4 intermediate was Difference absorption spectra were recorded after each addition.
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Microtiterplate Inhibition Assay A common mechanism for blockade of heme polymerization by
antimalarial quinolines. J. Biol. Chem. 273, 31103–31107.Two 96-well, flat-bottom microplates were used per test compound.
In one microplate, HRP-2, test compound, and heme were mixed 8. Wellems, T.E., and Howard, R.J. (1986). Homologous genes
encode two distinct histidine-rich proteins in a cloned isolatein 250 l total volume. The second microplate, the reference plate,
contained only the test compound and heme (with identical concen- of plasmodium falciparum. Proc. Natl. Acad. Sci. USA 83, 6065–
6069.trations as the first microplate). Each of the components were pre-
pared as follows. 9. Panton, L.J., McPhie, P., Maloy, W.L., Wellems, T.E., Taylor,
D.W., and Howard, R.J. (1989). Purification and partial charac-A stock solution of 1 mM heme was made in 0.1 M NaOH. This
stock heme solution was serially diluted in 100 mM HEPES (pH 7.0) terization of an unusual protein of plasmodium falciparum: Histi-
dine-rich protein II. Mol. Biochem. Parasitol. 35, 149–160.to the desired concentration. In a typical microtiterplate experiment,
ten heme solutions, concentrations ranging from 0 to 100 M, were 10. Sullivan, D.J., Gluzman, I.Y., and Goldberg, D.E. (1996). Plasmo-
dium hemozoin formation mediated by histidine-rich protein.used. In each well, 100 l of each heme solution was added such
that the final heme concentrations ranged from 0 to 40 M. Science 271, 219–221.
11. Choi, C.Y.H., Cerda, J.F., Chu, H.-A., Babcock, G.T., and Mar-A stock solution of each test compound was prepared in H2O to
10 mM. These stock solutions were serially diluted in H2O to the letta, M.A. (1999). Spectroscopic characterization of the heme-
binding sites in plasmodium falciparum histidine-rich protein 2.desired concentration (specific concentrations are described in the
figure legends). Either the test compound or H2O (50 L) was added Biochemistry 38, 16916–16924.
12. Chou, A.C., Chevli, R., and Fitch, C.D. (1980). Ferriprotopor-to each well.
HRP-2 was diluted to 2.5 times the desired final concentration phyrin IX fulfills the criteria for identification as the chloroquine
receptor of malaria parasites. Biochemistry 19, 1543–1549.using 100 mM HEPES (pH 7.0). HRP-2 concentration is specified in
the figure legends, but 0.3 or 0.4 M final concentration of HRP-2 13. Moreau, S., Perly, B., and Biguet, J. (1982). Interaction of chlo-
roquine with ferriprotophorphyrin IX. Nuclear magnetic reso-was used for a typical experiment. Either HRP-2 or buffer (100 L)
was added to each well. nance study. Biochimie 64, 1015–1025.
14. Vippagunta, S.R., Dorn, A., Matile, H., Bhattacharjee, A.K., Karle,The assay components in each well were mixed thoroughly using
the microplate reader. After incubating each microplate at room J.M., Ellis, W.Y., Ridley, R.G., and Vennerstrom, J.L. (1999).
Structural specificity of chloroquine-hematin binding related totemperature for 10 min, the absorbance at 415 nm was measured.
All samples were done in duplicate, and their values were averaged. inhibition of hematin polymerization and parasite growth. J.
Med. Chem. 42, 4630–4639.Heme binding to HRP-2 is monitored by observing the Soret peak
absorbance [i.e., A415 (HRP-2-heme-test compound)]. Absorbance contributions 15. Slater, A.F.G., Swiggard, W.J., Orton, B.R., Flitter, W.D., Gold-
berg, D.E., Cerami, A., and Henderson, C.B. (1991). An iron-from free heme and the test compound [i.e., A415 (heme-test compound)] are
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Natl. Acad. Sci. USA 88, 325–329.was run with each test compound. A415 was plotted against the
heme concentration to generate the heme binding curve at various 16. Bohle, D.S., and Helms, J.B. (1993). Synthesis of 	-hematin by
dehydrohalogenation of hemin. Biochem. Biophys. Res. Com-test compound concentrations where:
mun. 193, 504–508.
A415  A415 [HRP-2-heme-test compound]  17. Egan, T.J., Hempelmann, E., and Mavuso, W.W. (1999). Charac-
terization of synthetic 	-haematin and effects of the antimalarial
A415 [heme-test compound] drugs quinidine, halofantrine, desbutylhalofantrine and meflo-
quine on its formation. J. Inorg. Biochem. 73, 101–107.
18. Pandey, A.V., and Tekwani, B.L. (1996). Formation of haemo-
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